
Victor Ortiz-GarcÃ-a de la Foz

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2694945/publications.pdf

Version: 2024-02-01



Victor Ortiz-GarcÃa de la

#	Article	IF	CITATIONS
1	Cortical thickness across the lifespan: Data from 17,075 healthy individuals aged 3–90 years. Human Brain Mapping, 2022, 43, 431-451.	3.6	143
2	Virtual Histology of Cortical Thickness and Shared Neurobiology in 6 Psychiatric Disorders. JAMA Psychiatry, 2021, 78, 47.	11.0	136
3	Predicting relapse after a first episode of non-affective psychosis: A three-year follow-up study. Journal of Psychiatric Research, 2012, 46, 1099-1105.	3.1	118
4	Using Machine Learning and Structural Neuroimaging to Detect First Episode Psychosis: Reconsidering the Evidence. Schizophrenia Bulletin, 2020, 46, 17-26.	4.3	76
5	Genetic variants associated with longitudinal changes in brain structure across the lifespan. Nature Neuroscience, 2022, 25, 421-432.	14.8	75
6	Subcortical volumes across the lifespan: Data from 18,605 healthy individuals aged 3–90 years. Human Brain Mapping, 2022, 43, 452-469.	3.6	72
7	Towards Precision Medicine in Psychosis: Benefits and Challenges of Multimodal Multicenter Studies—PSYSCAN: Translating Neuroimaging Findings From Research into Clinical Practice. Schizophrenia Bulletin, 2020, 46, 432-441.	4.3	56
8	Neuroharmony: A new tool for harmonizing volumetric MRI data from unseen scanners. NeuroImage, 2020, 220, 117127.	4.2	48
9	Clinical Outcome After Antipsychotic Treatment Discontinuation in Functionally Recovered First-Episode Nonaffective Psychosis Individuals. Journal of Clinical Psychiatry, 2016, 77, 492-500.	2.2	47
10	Incidence of non-alcoholic fatty liver disease and metabolic dysfunction in first episode schizophrenia and related psychotic disorders: a 3-year prospective randomized interventional study. Psychopharmacology, 2016, 233, 3947-3952.	3.1	40
11	Comparison of the anti-inflammatory effect of aripiprazole and risperidone in 75 drug-naÃ⁻ve first episode psychosis individuals: A 3†months randomized study. Schizophrenia Research, 2018, 202, 226-233.	2.0	37
12	Understanding sex differences in long-term outcomes after a first episode of psychosis. NPJ Schizophrenia, 2020, 6, 33.	3.6	36
13	Prediction of acute clinical response following a first episode of non affective psychosis: Results of a cohort of 375 patients from the Spanish PAFIP study. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2013, 44, 162-167.	4.8	35
14	Comparison of metabolic effects of aripiprazole, quetiapine and ziprasidone after 12weeks of treatment in first treated episode of psychosis. Schizophrenia Research, 2014, 159, 90-94.	2.0	34
15	Brain structural and clinical changes after first episode psychosis: Focus on cannabinoid receptor 1 polymorphisms. Psychiatry Research - Neuroimaging, 2015, 233, 112-119.	1.8	34
16	Tobacco smoking and its association with cognition in first episode psychosis patients. Schizophrenia Research, 2018, 192, 269-273.	2.0	34
17	Rates and predictors of relapse in first-episode non-affective psychosis: a 3-year longitudinal study in a specialized intervention program (PAFIP). European Archives of Psychiatry and Clinical Neuroscience, 2017, 267, 315-323.	3.2	32
18	Long-term metabolic effects of aripiprazole, ziprasidone and quetiapine: a pragmatic clinical trial in drug-na¬ve patients with a first-episode of non-affective psychosis. Psychopharmacology, 2018, 235, 245-255.	3.1	30

#	Article	IF	CITATIONS
19	Effect of antipsychotic drugs on cortical thickness. A randomized controlled one-year follow-up study of haloperidol, risperidone and olanzapine. Schizophrenia Research, 2012, 141, 22-28.	2.0	28
20	Incidence and risk factors of acute akathisia in 493 individuals with first episode non-affective psychosis: a 6-week randomised study of antipsychotic treatment. Psychopharmacology, 2017, 234, 2563-2570.	3.1	27
21	Long-term (3-year) effectiveness of haloperidol, risperidone and olanzapine: results of a randomized, flexible-dose, open-label comparison in first-episode nonaffective psychosis. Psychopharmacology, 2012, 219, 225-233.	3.1	24
22	Three-year longitudinal population-based volumetric MRI study in first-episode schizophrenia spectrum patients. Psychological Medicine, 2014, 44, 1591-1604.	4.5	23
23	Stopping cannabis use benefits outcome in psychosis: findings from 10â€year followâ€up study in the PAFIPâ€cohort. Acta Psychiatrica Scandinavica, 2019, 140, 349-359.	4.5	23
24	Neuroanatomical abnormalities in first-episode psychosis across independent samples: a multi-centre mega-analysis. Psychological Medicine, 2021, 51, 340-350.	4.5	23
25	Plasma prolactin levels are associated with the severity of illness in drug-naive first-episode psychosis female patients. Archives of Women's Mental Health, 2019, 22, 367-373.	2.6	22
26	Aripiprazole, Ziprasidone and Quetiapine in the treatment of first-episode nonaffective psychosis: A 12-week randomized, flexible-dose, open-label trial. Schizophrenia Research, 2013, 147, 375-382.	2.0	21
27	Treatment of first-episode non-affective psychosis: a randomized comparison of aripiprazole, quetiapine and ziprasidone over 1Âyear. Psychopharmacology, 2014, 231, 357-366.	3.1	21
28	Aripiprazole, Ziprasidone, and Quetiapine in the Treatment of First-Episode Nonaffective Psychosis. Journal of Clinical Psychopharmacology, 2013, 33, 215-220.	1.4	20
29	Effects of aripiprazole, quetiapine and ziprasidone on plasma prolactin levels in individuals with first episode nonaffective psychosis: Analysis of a randomized open-label 1 year study. Schizophrenia Research, 2017, 189, 134-141.	2.0	20
30	Cannabis consumption and non-alcoholic fatty liver disease. A three years longitudinal study in first episode non-affective psychosis patients. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2019, 95, 109677.	4.8	20
31	Sex-specific variation of MRI-based cortical morphometry in adult healthy volunteers: The effect on cognitive functioning. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2011, 35, 616-623.	4.8	19
32	The effect of excess weight on circulating inflammatory cytokines in drug-naÃ ⁻ ve first-episode psychosis individuals. Journal of Neuroinflammation, 2018, 15, 63.	7.2	19
33	A 3-year prospective study on the metabolic effect of aripiprazole, quetiapine and ziprasidone: A pragmatic clinical trial in first episode psychosis patients. European Neuropsychopharmacology, 2020, 39, 46-55.	0.7	19
34	Effect of cannabis on weight and metabolism in first-episode non-affective psychosis: Results from a three-year longitudinal study. Journal of Psychopharmacology, 2019, 33, 284-294.	4.0	18
35	Duration of active psychosis and functional outcomes in first-episode non-affective psychosis. European Psychiatry, 2018, 52, 29-37.	0.2	17
36	No progression of the alterations in the cortical thickness of individuals with schizophrenia-spectrum disorder: a three-year longitudinal magnetic resonance imaging study of first-episode patients. Psychological Medicine, 2015, 45, 2861-2871.	4.5	16

#	Article	IF	CITATIONS
37	A cross-sectional and longitudinal structural magnetic resonance imaging study of the post-central gyrus in first-episode schizophrenia patients. Psychiatry Research - Neuroimaging, 2015, 231, 42-49.	1.8	16
38	Long-Term Antipsychotic Effectiveness in First Episode of Psychosis: A 3-Year Follow-Up Randomized Clinical Trial Comparing Aripiprazole, Quetiapine, and Ziprasidone. International Journal of Neuropsychopharmacology, 2018, 21, 1090-1101.	2.1	16
39	10Kin1day: A Bottom-Up Neuroimaging Initiative. Frontiers in Neurology, 2019, 10, 425.	2.4	15
40	Dissecting the functional outcomes of first episode schizophrenia spectrum disorders: a 10-year follow-up study in the PAFIP cohort. Psychological Medicine, 2021, 51, 264-277.	4.5	15
41	Brain grey matter abnormalities in first episode non-affective psychosis patients with suicidal behaviours: The role of neurocognitive functioning. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2020, 102, 109948.	4.8	14
42	Treatment Discontinuation Impact on Long-Term (10-Year) Weight Gain and Lipid Metabolism in First-Episode Psychosis: Results From the PAFIP-10 Cohort. International Journal of Neuropsychopharmacology, 2021, 24, 1-7.	2.1	12
43	Understanding the direct and indirect costs of a first episode of psychosis program: Insights from PAFIP of Cantabria, Spain, during the first year of intervention. Microbial Biotechnology, 2019, 13, 1182-1190.	1.7	11
44	Duration of active psychosis during early phases of the illness and functional outcome: The PAFIP 10-year follow-up study. Schizophrenia Research, 2020, 220, 240-247.	2.0	11
45	One year longitudinal study of the straight gyrus morphometry in first-episode schizophrenia-spectrum patients. Psychiatry Research - Neuroimaging, 2012, 202, 80-83.	1.8	9
46	Progressive Structural Brain Changes and NRG1 Gene Variants in First-Episode Nonaffective Psychosis. Neuropsychobiology, 2015, 71, 103-111.	1.9	9
47	Comparison of aripiprazole and risperidone effectiveness in first episode non-affective psychosis: Rationale and design of a prospective, randomized, 3-phase, investigator-initiated study (PAFIP-3). Revista De PsiquiatrÃa Y Salud Mental, 2021, 14, 157-163.	1.8	9
48	The effects of tobacco smoking on age of onset of psychosis and psychotic symptoms in a first-episode psychosis population. Addiction, 2017, 112, 526-532.	3.3	8
49	Long term cortical thickness changes after a first episode of non- affective psychosis: The 10Âyear follow-up of the PAFIP cohort. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2021, 108, 110180.	4.8	8
50	Education and long-term outcomes in first episode psychosis: 10-year follow-up study of the PAFIP cohort. Psychological Medicine, 2023, 53, 66-77.	4.5	8
51	Active psychosis and pro-inflammatory cytokines in first-episode of psychosis. Journal of Psychiatric Research, 2021, 134, 150-157.	3.1	7
52	Aripiprazole vs Risperidone for the acute-phase treatment of first-episode psychosis: A 6-week randomized, flexible-dose, open-label clinical trial. European Neuropsychopharmacology, 2021, 47, 74-85.	0.7	7
53	BDNF Val66Met variants and brain volume changes in non-affective psychosis patients and healthy controls: A 3year follow-up study. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2013, 45, 201-206.	4.8	6
54	Age of onset of Cannabis use and cognitive function in first-episode non-affective psychosis patients: Outcome at three-year follow-up. Schizophrenia Research, 2018, 201, 159-166.	2.0	6

#	Article	IF	CITATIONS
55	Expression and Functionality Study of 9 Toll-Like Receptors in 33 Drug-NaÃ⁻ve Non-Affective First Episode Psychosis Individuals: A 3-Month Study. International Journal of Molecular Sciences, 2020, 21, 6106.	4.1	6
56	Classification of first-episode psychosis using cortical thickness: A large multicenter MRI study. European Neuropsychopharmacology, 2021, 47, 34-47.	0.7	6
57	Prolactin, metabolic and immune parameters in naÃ⁻ve subjects with a first episode of psychosis. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2021, 110, 110332.	4.8	6
58	A family study on first episode of psychosis patients: Exploring neuropsychological performance as an endophenotype. Acta Psychiatrica Scandinavica, 2022, 145, 384-396.	4.5	6
59	Aripiprazole and Risperidone Present Comparable Long-Term Metabolic Profiles: Data From a Pragmatic Randomized Controlled Trial in Drug-NaÃ⁻ve First-Episode Psychosis. International Journal of Neuropsychopharmacology, 2022, 25, 795-806.	2.1	5
60	Straight gyrus morphology in first-episode schizophrenia-spectrum patients. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2011, 35, 84-90.	4.8	4
61	Comparison of aripiprazole and risperidone effectiveness in first episode non-affective psychosis: Rationale and design of a prospective, randomized, 3-phase, investigator-initiated study (PAFIP-3). Revista De PsiquiatrÃa Y Salud Mental (English Edition), 2021, 14, 157-163.	0.3	4
62	Predictors of diagnostic stability in brief psychotic disorders: Findings from a 3â€year longitudinal study. Acta Psychiatrica Scandinavica, 2021, 144, 578-588.	4.5	4
63	Data regarding the effect of cannabis consumption on liver function in the prospective PAFIP cohort of first episode psychosis. Data in Brief, 2019, 27, 104415.	1.0	3
64	Cognitive reserve as a moderator of outcomes in five clusters of first episode psychosis patients: a 10-year follow-up study of the PAFIP cohort. Psychological Medicine, 2023, 53, 1891-1905.	4.5	3
65	Disentangling early and late onset of psychosis in women: identifying new targets for treatment. Archives of Women's Mental Health, 2022, 25, 335-344.	2.6	3
66	Elevated risk of liver steatosis in first-episode psychosis patients: Results from a 3-year prospective study. Schizophrenia Research, 2022, 246, 30-38.	2.0	3
67	S101. DIFFERENTIATING NON-AFFECTIVE ACUTE REMITTING PSYCHOSIS (NARP) FROM SCHIZOPHRENIA IN FIRST-EPISODE PSYCHOSIS: FINDINGS FROM A 3-YEAR LONGITUDINAL STUDY IN THE PAFIP COHORT. Schizophrenia Bulletin, 2020, 46, S72-S73.	4.3	2
68	Long-term clinical and functional outcome after antipsychotic discontinuation in early phases of non-affective psychosis: Results from the PAFIP-10 cohort. Schizophrenia Research, 2021, 232, 28-30.	2.0	2
69	Long-term metabolic effect of second-generation antipsychotics in first episode of psychosis. European Psychiatry, 2017, 41, S388-S388.	0.2	1
70	Predictive value of prolactin in first episode psychosis at ten years follow-up. Revista De PsiquiatrÃa Y Salud Mental, 2021, 14, 179-180.	1.8	1
71	Stability of schizophrenia diagnosis in a 10â€year longitudinal study on first episode of nonâ€affective psychosis: Conclusions from the PAFIP cohort. Acta Psychiatrica Scandinavica, 2021, 144, 342-357.	4.5	1
72	Different neurocognitive profiles of risperidone and aripiprazole in the FIRST episode of psychosis: A 3-year follow-up comparison. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2021, 110, 110309.	4.8	1

#	Article	IF	CITATIONS
73	Naturalistic study on the use of clozapine in the early phases of non-affective psychosis: A 10-year follow-up study in the PAFIP-10 cohort. Journal of Psychiatric Research, 2022, 153, 292-299.	3.1	1
74	A Cross-Sectional and Longitudinal Magnetic Resonance study of Insular Cortex in First-Episode Non-Affective Psicosis. Effect of Gender and Diagnostic specificity NeuroImage, 2009, 47, S174.	4.2	0
75	Effect of Disrupted-in-Schizophrenia 1 gene on treatment response in patients with a first episode of psychosis. European Psychiatry, 2016, 33, S183-S183.	0.2	0
76	Lack of differential long-term metabolic profile of aripiprazole, quetapine and ziprasidone in first episode of psychosis. European Psychiatry, 2017, 41, S388-S388.	0.2	0
77	O6.7. COMMON NEUROANATOMICAL ABNORMALITIES IN FIRST EPISODE PSYCHOSIS ACROSS SEVERAL INDEPENDENT SAMPLES. Schizophrenia Bulletin, 2018, 44, S92-S92.	4.3	0
78	T175. A 10-YEAR LONGITUDINAL STUDY OF GREY MATTER VOLUME IN FIRST EPISODE OF NON-AFFECTIVE PSYCHOSIS. Schizophrenia Bulletin, 2018, 44, S184-S184.	4.3	0
79	F55INFLUENCE OF SCHIZOPHRENIA POLYGENIC RISK SCORES ON BRAIN SURFACE: AN EXPLORATORY STUDY IN FIRST EPISODE OF PSYCHOSIS. European Neuropsychopharmacology, 2019, 29, S1139.	0.7	0
80	SA114POLYGENIC RISK SCORE AND METABOLIC SYNDROME PREDICTION IN PATIENTS WITH A FIRST EPISODE OF NON-AFFECTIVE PSYCHOSIS. European Neuropsychopharmacology, 2019, 29, S1251.	0.7	0
81	M97. PREDICTORS OF TRANSITION TO SCHIZOPHRENIA IN BRIEF PSYCHOTIC DISORDER: FINDINGS FROM A 3-YEAR LONGITUDINAL STUDY IN THE PAFIP COHORT. Schizophrenia Bulletin, 2020, 46, S171-S172.	4.3	0
82	Data regarding active psychosis and functional outcome, among other clinical variables, during early phases of the illness in first-episode psychosis in the PAFIP 10-year follow-up program. Data in Brief, 2020, 30, 105599.	1.0	0
83	Predictive value of prolactin in first episode psychosis at ten years follow-up. Revista De PsiquiatrÃa Y Salud Mental (English Edition), 2021, 14, 179-180.	0.3	0